Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Biological: IGF1R antibody MK0646Other: Saline solution
- Registration Number
- NCT02711865
- Lead Sponsor
- Hillel Yaffe Medical Center
- Brief Summary
The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
- Patients with ovarian cancer
Exclusion Criteria
- All others
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description MK-0646 IGF1R antibody MK0646 Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal. Control Saline solution Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
- Primary Outcome Measures
Name Time Method Responsive to IGF1R therapy One year Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.
- Secondary Outcome Measures
Name Time Method Proteomic Signature of IGF1R Responsive Tumors One year Mass Spectrometry will be used to compare IGF1R responsive and non-responsive tumors to identify the proteins associated with sensitivity to IGF1R therapy.
Trial Locations
- Locations (1)
Hillel Yaffe Medical Center
🇮🇱Hadera, Israel